|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-5.68/2.98
|
企業價值
22.42B
|
資產負債 |
每股賬面淨值
68.95
|
現金流量 |
現金流量率
--
|
損益表 |
收益
36.42M
|
每股收益
16.72
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/16 21:29 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |